Wensheng Fan, CEO of Spectral MD, Discusses How Artificial Intelligence (AI) Can Revolutionize the Standard of Care in Burn Wound Diagnostics

DeepView AI- Burn Platform is Designed to Improve Diagnostic Accuracy, Enhance Patient Outcomes, and Reduce Healthcare Costs

Spectral MD Holdings, Ltd, an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, continues to make progress in developing and commercializing its AI-enabled DeepView burn imaging platform. The DeepView AI-enabled platform addresses a current deficiency in wound healing assessment protocols, specifically, a lack of diagnostic tools and a reliance on the provider’s experience. Instead of looking at a burn wound from the outside in, DeepView allows clinicians to view it from the inside out. By allowing healthcare providers to see what can’t be seen by the naked eye, the DeepView platform provides a quick and accurate assessment of the severity of a wound and informs next step treatment.

AiThority Interview Insights: AiThority Interview with Darren Guarnaccia, President at Uniform

“The application of AI in healthcare, generally, and the introduction of new technologies such as Spectral MD’s DeepView^® platform, specifically, reflect the next phase of an ever-expanding and increasingly holistic approach to patient care”

“The application of AI in healthcare, generally, and the introduction of new technologies such as Spectral MD’s DeepView^® platform, specifically, reflect the next phase of an ever-expanding and increasingly holistic approach to patient care,” said Wensheng Fan, Co-Founder and CEO of Spectral MD. “We see significant potential for AI-enabled diagnostics in burn wound assessment to augment the training and expertise of clinicians while promoting expedited treatment decisions, efficient workflows, and lower healthcare costs.”

“In the United States and the UK there are over 490,000 and 87,000 burn victims, respectively, who receive emergency medical treatment each year,” said Mr. Fan. “The initial assessment of these injuries is crucial in determining appropriate treatment, specifically, will a wound heal on its own or does it require surgical intervention? Unfortunately, even burn care specialists only accurately assess on Day 1 the trajectory of a wound’s healing process an estimated 50% to 70% of the time. This can result in sub-optimal patient outcomes, including unnecessary surgeries, and added stresses across the healthcare continuum.”

Read More about AiThority Interview: AiThority Interview with Brett Weigl, SVP and GM, Digital, AI and Journey Analytics at Genesys

Spectral MD’s DeepView imaging platform – which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“U.S. FDA”) in 2018 for its burn indication – integrates optical technology and AI-enabled algorithms using over 263 billion pixels of proprietary data to see deep below the surface of the burn to distinguish between healthy and damaged tissue. In less than 60 seconds, the DeepView^® platform delivers a binary wound healing prediction to assist physicians in determining whether a burn will heal on its own or if surgery is required. Studies conducted by Spectral MD have demonstrated a burn diagnostic accuracy rate of 92% on Day 1, well above the estimated 50% to 70% accuracy of burn specialists.

Spectral MD’s DeepView^® imaging platform has been supported by approximately $130 million of U.S. Government funding since 2013. Clinical trials are underway and Spectral MD is nearing commercialization for DeepView^® with planned submissions to the U.S. FDA for the burn indication in 2025.

 Latest AiThority Interview Insights : AiThority Interview with Mary-Lou Smulders, Chief Marketing Officer at Dedrone

 [To share your insights with us, please write to sghosh@martechseries.com]